Publications
2024
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study
Madeleine J. Karpinski, Johannes Hüsing, Kevin Claassen, Lennart Möller, Hiltraud Kajüter, Florian Oesterling, Viktor Grünwald, Lale Umutlu, Jens Kleesiek, Tugce Telli, Anja Merkel-Jens, Anika Hüsing, Claudia Kesch, Ken Herrmann, Matthias Eiber, Sebastian Hoberück, Philipp Tobias Meyer, Felix Kind, Kambiz Rahbar, Michael Schäfers, Andreas Stang, Boris Hadaschik, Wolfgang P. Fendler
The Lancet Oncology 2020
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Robert Seifert, Katharina Kessel, Katrin Schlack, Manuel Weber, Ken Herrmann, Maximilian Spanke, Wolfgang P. Fendler, Boris Hadaschik, Jens Kleesiek, Michael Schäfers, Matthias Weckesser, Martin Boegemann, Kambiz Rahbar
European Journal of Nuclear Medicine and Molecular Imaging
Semi-automatically quantified tumor volume using Ga-68-PSMA-11-PET as biomarker for survival in patients with advanced prostate cancer
Robert Seifert, Ken Herrmann, Jens Kleesiek, Michael Schäfers, Vijay Shah, Zhoubing Xu, Guillaume Chabin, Sasa Garbic, Bruce Spottiswoode, Kambiz Rahbar
Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving $^textrm177$ Lu-PSMA-617 Radioligand Therapy
Robert Seifert, Konstantin Seitzer, Ken Herrmann, Katharina Kessel, Michael Schäfers, Jens Kleesiek, Matthias Weckesser, Martin Boegemann, Kambiz Rahbar
Theranostics 
